ES8304800A1 - "procedimiento de preparacion de una composicion terapeutica en la que el unico agente hemostatico activado efectivo sea el factor viia". - Google Patents

"procedimiento de preparacion de una composicion terapeutica en la que el unico agente hemostatico activado efectivo sea el factor viia".

Info

Publication number
ES8304800A1
ES8304800A1 ES513485A ES513485A ES8304800A1 ES 8304800 A1 ES8304800 A1 ES 8304800A1 ES 513485 A ES513485 A ES 513485A ES 513485 A ES513485 A ES 513485A ES 8304800 A1 ES8304800 A1 ES 8304800A1
Authority
ES
Spain
Prior art keywords
factor viia
composition based
hemostatic agent
preparing same
agent factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513485A
Other languages
English (en)
Other versions
ES513485A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter Travenol Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Laboratories Inc filed Critical Baxter Travenol Laboratories Inc
Publication of ES8304800A1 publication Critical patent/ES8304800A1/es
Publication of ES513485A0 publication Critical patent/ES513485A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE COMPOSICIONES QUE CONTIENEN EL AGENTE HEMOSTATICO ACTIVADO FACTOR VIIA; COMPOSICIONES QUE TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE PACIENTES CON DEFICIENCIAS O INHIBIDORES DE FACTOR HEMOCOAGULANTES. CONSISTE EN LA SEPARACION DEL FACTOR VII RESPECTO DEL FACTOR IX, DE UN MATERIAL QUE CONTIENE AMBOS; Y ACTIVACION DE LA FRACCION QUE CONTIENE EL FACTOR VII MEDIANTE LA SELECCION DE UNA CONDICION QUE PUEDA MODIFICARSE PARA CONTROLAR EL GRADO DE ACTIVACION DEL FACTOR VII, FIJACION DE LA MAGNITUD DE LA CONDICION NECESARIA PARA LA ACTIVACION A UN GRADO DETERMINADO, ADAPTACION DE LA CONDICION A TAL MAGNITUD, Y REALIZACION DE LA ACTIVACION DE ACUERDO CON LA CONDICION.
ES513485A 1981-06-25 1982-06-25 "procedimiento de preparacion de una composicion terapeutica en la que el unico agente hemostatico activado efectivo sea el factor viia". Granted ES513485A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/277,469 US4382083A (en) 1981-06-25 1981-06-25 Therapeutic method for treating blood-clotting defects with factor VIIa

Publications (2)

Publication Number Publication Date
ES8304800A1 true ES8304800A1 (es) 1983-04-01
ES513485A0 ES513485A0 (es) 1983-04-01

Family

ID=23061015

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513485A Granted ES513485A0 (es) 1981-06-25 1982-06-25 "procedimiento de preparacion de una composicion terapeutica en la que el unico agente hemostatico activado efectivo sea el factor viia".

Country Status (11)

Country Link
US (1) US4382083A (es)
EP (1) EP0082182B1 (es)
JP (1) JPS58500994A (es)
BR (1) BR8207762A (es)
CA (1) CA1186994A (es)
DE (1) DE3276849D1 (es)
ES (1) ES513485A0 (es)
IT (1) IT1163004B (es)
MX (1) MX7191E (es)
WO (1) WO1983000016A1 (es)
ZA (1) ZA824233B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ZA862768B (en) 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
AU593042B2 (en) * 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US6013531A (en) * 1987-10-26 2000-01-11 Dade International Inc. Method to use fluorescent magnetic polymer particles as markers in an immunoassay
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
US5677160A (en) * 1989-10-30 1997-10-14 Henkel Corporation Fat splitting process
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US20040072757A1 (en) * 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
CA2136633A1 (en) * 1992-06-12 1993-12-23 James D. Allbery, Jr. Intelligent process control communication system and method
JPH11506006A (ja) * 1995-05-31 1999-06-02 ヘンケル コーポレーション 油脂の改良分解法
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DK0796623T3 (da) * 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
DE59800935D1 (en) 1997-04-08 2001-08-02 Baxter Ag Immuntolerante prothrombinkomplex-präparation
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP4676585B2 (ja) * 1999-12-24 2011-04-27 一般財団法人化学及血清療法研究所 血液凝固異常に基づく疾患の治療・予防用医薬組成物
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
JP2005510513A (ja) 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびｔａｆｉポリペプチドを含む薬学的組成物
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions

Also Published As

Publication number Publication date
WO1983000016A1 (en) 1983-01-06
IT8222056A0 (it) 1982-06-24
JPH0428690B2 (es) 1992-05-15
MX7191E (es) 1987-12-23
EP0082182A1 (en) 1983-06-29
ZA824233B (en) 1983-04-27
JPS58500994A (ja) 1983-06-23
BR8207762A (pt) 1983-05-31
IT1163004B (it) 1987-04-08
CA1186994A (en) 1985-05-14
ES513485A0 (es) 1983-04-01
EP0082182A4 (en) 1983-11-09
EP0082182B1 (en) 1987-07-29
US4382083A (en) 1983-05-03
DE3276849D1 (en) 1987-09-03

Similar Documents

Publication Publication Date Title
ES8304800A1 (es) "procedimiento de preparacion de una composicion terapeutica en la que el unico agente hemostatico activado efectivo sea el factor viia".
AU6567086A (en) Compositions and methods for the treatment of bleeding disorders
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
IL72354A0 (en) Imidazolium salts,processes for the preparation thereof and pharmaceutical compositions containing the same
CY1737A (en) Desulfatohirudine process for its preparation and pharmaceutical agent
MX165863B (es) Barrera que evita la adhesion, que contiene heparina y procedimiento para prepararla
EP0091964A4 (en) BASIC COMPOSITION FOR THE PREPARATION OF DRUGS FOR EXTERNAL APPLICATION, MEDICINAL COMPOSITION FOR EXTERNAL APPLICATION, AND METHOD FOR ACCELERATING THE PERCUTANEOUS ABSORPTION OF A MEDICINAL AGENT.
GB2025413B (en) 4,5 13-prostatrienoic acid derivatives
ES8605956A1 (es) Procedimiento para preparar una composicion antiacido
NZ219374A (en) Topical pharmaceutical containing tamoxifen
GB2124487B (en) Agent for the treatment of wounds
DE3165600D1 (en) Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
AU7657287A (en) Synergistic blood clot treatment composition comprising tissue plasminogen activator and a prostaglandin
ES2031846T3 (es) Compuesto medico que contiene tpa y uso del mismo.
PT80214B (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
SE8304821D0 (sv) Arabinogalaktaner, deras framstellning och kompositioner innehallande desamma
EP0124252A3 (en) Double ester of 16beta-ethylestran-17beta-ol derivatives
EP0204172A3 (en) Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
CS330884A2 (en) Zpusob vyroby 2-alkythio-1-aminoalkyl-5-oxo-2-pyrrolin-3-karbonitrilu
JPS5214769A (en) Preparation of n2-cumarin sulfonylalginamides and acid addition salts thereof
DK563886A (da) Terapeutisk komposition

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20030127